Brind.

EMA gives positive opinion on Biocon's Pertuzumab biosimilar

3 reports, 2 independent Updated Sep 21
Gone quiet Reached 2 outlets in its first 24 hours
Reports
3
Developments
2
Repetition
33%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

The European Medicines Agency's Committee for Medicinal Products for Human Use gave a positive opinion on Biocon's Pertuzumab biosimilar, branded as Pebrilzo, for the treatment of HER2-positive breast cancer. Biocon stated that this biosimilar is the first to receive a positive opinion under the EMA's tailored clinical approach. The European Commission will now proceed with the final review of the application and issue its decision.

From business-standard.com, equitybulls.com

Why it matters

Some supportBrind's analysis of the reports

The positive opinion from the European Medicines Agency marks a significant regulatory milestone for Biocon in the European market. Following the announcement, Biocon's share price jumped nearly 3%. The final approval by the European Commission could expand access to biologic therapies for patients in Europe.

From business-standard.com, equitybulls.com

Who's involved

  • European Medicines AgencyRegulatory authority reviewing the biosimilar application for market access.
  • BioconIndian biopharmaceutical company whose biosimilar received the positive opinion.
  • Kiran Mazumdar-ShawFounder and Chairperson of Biocon.
  • European CommissionExecutive branch of the European Union that will issue the final market authorization decision.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • BioconSpeculative

    Biocon might see increased revenue from market access in Europe.

  • WockhardtSpeculative

    Wockhardt may see sector-wide positive sentiment affecting investment in pharmaceutical companies.

  • MylanSpeculative

    Mylan could see the value of its equity stake in Biocon increase due to market strength.

How it developed

Newest first. Tap a step to see who reported it.
  1. EMA seeks positive opinion on Pertuzumab biosimilar market access.1 source
  2. EMA committee gives positive opinion on Biocon's market access.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped